Overview

* Harmony Biosciences Q2 2025 revenue grows 16% YoY but misses analyst expectations

* Company reaffirms 2025 revenue guidance, maintaining $820-$860 mln target

* Harmony on track for Phase 3 ZYN002 trial results in Fragile X syndrome, Q3 2025

Outlook

* Harmony reaffirms 2025 revenue guidance of $820 mln to $860 mln

* Company on track for Phase 3 ZYN002 data in Q3 2025

* Harmony plans Phase 3 trials for Pitolisant HD in Q4 2025

* Company to start first-in-human trial for Orexin-2 agonist in 2H 2025

Result Drivers

* WAKIX GROWTH - 16% YoY revenue growth driven by increase of 400 average patients in Q2 2025

* PATIENT EXPANSION - Commercial efforts reached 9,000 healthcare providers, expanding prescriber base

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $200.49 $203.60

Product mln mln (11

Revenue Analysts

)

Q2 Net $39.78

Income mln

Q2 Miss $49.64 $54.20

Pretax mln mln (9

Profit Analysts

)

Q2 Gross $162.34

Profit mln

Q2 $48.18

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Harmony Biosciences Holdings Inc ( HRMY ) is $48.00, about 26% above its August 4 closing price of $35.54

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)